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Abstract
Background: Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug chemotherapy
regimen represents the treatment cornerstone; however, cure is rarely achieved. We have been treating dogs with
B-cell lymphoma with an autologous vaccine (APAVAC®) and CHOP-based chemotherapy since 2011.
Methods: To better characterize the safety and efficacy of APAVAC®, and to find the best candidates for
immunotherapy, we designed a retrospective study on all dogs treated with chemo-immunotherapy to date and
compared them with those dogs treated with chemotherapy only. All dogs were completely staged and re-staged
at the end of treatment. The primary endpoint was the effectiveness of chemo-immunotherapy, measured as time
to progression (TTP), lymphoma-specific survival (LSS), and 1-, 2-, and 3-year survival rates. The secondary objective
was safety.
Results: Three hundred dogs were included: 148 (49.3%) received chemotherapy and 152 (50.7%) chemo-
immunotherapy. Overall, the latter survived significantly longer (median LSS, 401 vs 220; P < 0.001).
Among dogs with diffuse large B-cell lymphoma, the 1-, 2- and 3-year survival rates were 20, 13 and 8% for
chemotherapy, and 51, 19 and 10% for chemo-immunotherapy. The benefit of chemo-immunotherapy was
particularly relevant in dogs with concurrent high serum LDH, stage V, substage a disease and not previously
treated with steroids (median LSS, 480 vs 85 days; P < 0.001). Among dogs with nodal marginal zone lymphoma,
those having at least 3 of the aforementioned characteristics significantly benefited from chemo-immunotherapy
(median LSS, 680 vs 160 days, P < 0.001). The 1-, 2- and 3-year survival rates were 30, 16 and 10% for
chemotherapy, and 55, 28 and 10% for chemo-immunotherapy. Among dogs with follicular lymphoma, lack of
immunotherapy administration was the only variable significantly associated with increased risk of tumor-related
death. Chemo-immunotherapy was remarkably well tolerated, with no local or systemic adverse events.
Conclusions: Overall, the addition of immunotherapy to a traditional CHOP protocol is associated with improved
outcome in dogs with B-cell lymphoma, regardless of histotype and evaluated prognostic factors. Moreover, the
identikit of the best candidate for immune-therapy was delineated for the most common histotypes. The study also
confirms the excellent tolerability of the vaccine.
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Background
Pet dogs most often spontaneously develop B-cell
lymphoma [1], for which survival without treatment is
measured in weeks or months. Anthracycline-based
multidrug chemotherapy represents the cornerstone for
the treatment of canine B-cell lymphoma across all dis-
ease stages; however, the majority of dogs eventually re-
lapses and develops chemo-resistance, and cure is rarely
achieved [2].
Immunotherapy represents a powerful way to treat
cancer, and the last decade has witnessed unprece-
dented advancements in the understanding of both
the molecular drivers of lymphomagenesis and mech-
anisms by which lymphoma circumvents anti-tumor
immunity [3, 4].
In oncology, therapeutic vaccines have the theoret-
ical ability to generate cytotoxic T-lymphocytes that
reject cancer cells, and memory cells that prevent re-
lapse [5, 6].
Active immunotherapy consisting of hydroxylapatite
ceramic powder and HSPs purified from the dogs’ tu-
mors (APAVAC®) has shown promising results in a piv-
otal placebo-controlled, randomized clinical trial in dogs
with DLBCL [7]. Within the first few years of its intro-
duction to the European market, the investigational use
of APAVAC® was extended to indolent B-cell lymphomas
with suggestive signals of potential usefulness [8].
The aim of this retrospective study was to compare the
efficacy and safety of chemotherapy alone versus chemo-
immunotherapy in dogs with multicentric B-cell lymph-
oma of various histotypes in 5 years of clinical experience.
The survival advantage of chemo-immunotherapy was
further assessed after stratifying dogs according to poten-
tial prognostic variables, in order to identify the best can-
didates for vaccine administration.
Pooling the available clinical data should provide an
accurate evaluation of the efficacy of chemo-
immunotherapy in canine B-cell lymphoma compared
with traditional chemotherapy, posing the basis for fu-
ture clinical trial design and informing human trials.
Material and methods
Medical records were reviewed for every consecutive ca-
nine patient with previously untreated multicentric B-
cell lymphoma that presented to the Centro Oncologico
Veterinario (Sasso Marconi, Italy) and Department of
Veterinary Medicine (University of Milan, Italy) from
2013 to 2018. This study was prospectively conceived
and clinical data on the efficacy and toxicity of treat-
ments were analyzed retrospectively, thus the inclusion
criteria were established a priori and all dogs were
treated contemporaneously.
To be eligible for inclusion, dogs were required to
undergo a complete initial staging work-up and, whenever
possible, surgical removal of a peripheral LN to ob-
tain a histopathological diagnosis and material for the
vaccine generation (Additional file 1). Based on histo-
pathology and immunohistochemistry (CD20, CD3),
tumors were classified according to the modified
WHO criteria [9].
Also, dogs were only included, if information regard-
ing treatment and outcome were complete.
As this evaluation did not influence any therapeutic
decision, approval by an Ethics Committee was not re-
quired. Owners gave their written informed consent to
the use of clinical data.
Treatment protocol
Vaccinated dogs
The detailed method of vaccine preparation and the
protocol used for dogs treated with chemo-
immunotherapy has been described elsewhere, [[7] Add-
itional file 1].
Briefly, dogs received l-asparaginase, vincristine, cyclo-
phosphamide, doxorubicin, lomustine, prednisone, and a
total of 8 intradermal injections of 0.5 ml vaccine.
For immunological monitoring, the DTH skin test was
performed in all vaccinated dogs at the end of treatment
(Additional file 1).
Unvaccinated dogs
Unvaccinated dogs received two CHOP-based protocol,
including l-asparaginase, vincristine, cyclophosphamide,
doxorubicin, prednisone, with or without lomustine(Ad-
ditional file 1); the intended summation dose intensity of
these two protocols was 16.8 and 16.9, respectively.
Thus, they were considered identical and evaluated as a
whole.
Response assessment and minimal residual disease
monitoring
Response was evaluated at each treatment session ac-
cording to previously published criteria [10].
Two weeks after having completed the protocol, all
dogs underwent restaging by repeating the initially al-
tered examination. For minimal residual disease moni-
toring, FC on PB, BM and a LN aspirate was carried out
[11, 12]. Dogs were then rechecked through monthly
physical examinations during the first year, and every
other month thereafter.
Relapse was defined as clinical reappearance and cyto-
logical evidence of lymphoma in any anatomical site in
dogs having experienced CR, whereas relapse for animals
with PR was defined as progression.
Dogs that relapsed during or after treatment were of-
fered rescue chemotherapy.
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Endpoints
The primary study objectives were the effectiveness of
chemo-immunotherapy in dogs with B-cell lymphoma,
measured as TTP, LSS, and 1-, 2-, and 3-year survival
rates. This was evaluated in the whole population and by
stratifying dogs according to potential prognostic vari-
ables, in order to select the best candidates for chemo-
immunotherapy.
The secondary objective was safety (measured by re-
cording any AE and/or hospitalization that occurred
during or immediately after treatment). All AEs were
registered at the time of occurrence, and graded accord-
ing to VCOG [13].
Statistical analysis
Descriptive statistics were used in the analysis of dogs
and tumor characteristics. The distribution of demo-
graphic features and possible outcome variables between
treatment groups were assessed with Fisher’s exact test/
χ2 test (categorical variables).
Variables considered were: sex, age, weight, PCV,
platelet count, serum LDH activity, serum Ionized cal-
cium concentration, substage, PB infiltration, BM infil-
tration, extranodal site involvement, and pre-treatment
with steroids.
TTP was calculated as the interval between initiation
of treatment and PD or relapse; dogs with no PD or re-
lapse at data-analysis closure or death were censored.
LSS was measured as the interval between initiation of
treatment and death or euthanasia for lymphoma or
chemo-related causes. Dogs deceased for lymphoma-
unrelated causes or alive at data-analysis closure were
censored. Survival plots were generated according to the
Kaplan-Meier product-limit method. Curves were com-
pared with the log-rank test. The influence of potential
prognostic variables on tumor progression and tumor-
related death was investigated with univariable and mul-
tivariable Cox’s regression analysis.
The survival advantage of vaccine administration was
further tested upon stratification of cases according to
the other considered variables. The variables with no
survival advantage for one of the strata were selected for
a scoring system to quantify the utility of vaccine admin-
istration. Dogs with the highest score were the best can-
didates for immunotherapy.
Data were analyzed by use of commercial software
programs (SPSS Statistics v19, IBM, Armonk, NY, USA,
Prism v.5.0, GraphPad, San Diego, California). P-values
< 0.05 were considered significant.
Results
The total population consisted of 300 dogs: 246 (82%)
underwent lymphadenectomy, whereas in the remaining
54 (18%) a cytological and FC diagnosis only was
obtained.
Within the histology group, DLBCL was the most
common histotype (n = 148; 60.2%), followed by nodal
MZL late stage (n = 49; 19.9%), FL (n = 25; 10.2%), Bur-
kitt lymphoma (n = 10; 4.1%), SLL (n = 8; 3.3%), and
lymphoblastic lymphoma (n = 6; 2.4%).
Within the cytology group, there were 50 (92.6%%)
centroblastic/immunoblastic lymphomas, 2 (3.7%)
lymphoblastic lymphomas, and 2 (3.7%) medium
macronucleolated cell lymphomas.
Within the whole population, 148 (49.3%) dogs re-
ceived chemotherapy alone and 152 (50.7%) chemo-
immunotherapy.
Median TTP was 147 days (95% CI, 111–183) for
dogs receiving chemotherapy and 244 days (95% CI,
218–270) for those receiving chemo-immunotherapy
(P < 0.001). Median LSS was 220 days (95% CI, 157–
243) for dogs receiving chemotherapy and 401 days
(95% CI, 339–463) for those receiving chemo-
immunotherapy (P < 0.001).
The three main histotypes are detailed in the following
paragraphs.
Dogs with diffuse large B-cell lymphoma
Table 1 provides a summary of the characteristics of 148
dogs with DLBCL using known or potential covariates
for outcome.
Forty (27%) dogs had been treated with steroids be-
fore referral. Forty-seven (31.8%) were treated with
chemotherapy and 101 (68.2%) received chemo-
immunotherapy. There was a good balance between
treatment arms regarding demographic information
and possible outcome variables, including the number
of rescue protocols, with the exception of a lower
percentage of dogs with extranodal involvement in
the chemo-immunotherapy group (Table 1).
Median TTP was 98 days (95% CI, 9–187) for dogs re-
ceiving chemotherapy and 250 days (95% CI, 210–290)
for those receiving chemo-immunotherapy (P = 0.001).
Median LSS was 165 days (95% CI, 107–223) for dogs
receiving chemotherapy and 413 days (95% CI, 316–510)
for those receiving chemo-immunotherapy (P = 0.001).
There was no significant difference in TTP and LSS
between dogs with positive and negative DTH test.
The 1-year, 2-year and 3-year survival rates were, re-
spectively, 20, 13 and 8% for the chemotherapy group,
and 51, 19 and 10% for the chemo-immunotherapy
group.
On multivariable analysis, lack of immunotherapy
administration was significantly associated with an in-
creased risk of tumor progression (HR = 2.3, 95% CI =
1.4–3.6, P = 0.001) and tumor-related death (HR = 2.6,
95% CI = 1.6–4.2, P < 0.001). The benefit of chemo-
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Table 1 Baseline characteristics of 222 dogs with B-cell lymphoma treated with chemotherapy alone or with chemo-
immunotherapy and stratified according to histotype
Variable DLBCL (n = 148) MZL (n = 49) Follicular lymphoma (n = 25)
CH
(n = 47)
CH-IT
(n = 101)
P CH
(n = 24)
CH-IT
(n = 25)
P CH
(n = 6)
CH-IT
(n = 19)
P
Sex 0.522 0.484 0.175
Male 25 48 12 15 4 6
Female 22 53 12 10 2 13
Median age
(range) - years
9 (3–12) 7 (3–15) 0.677 8 (3–15) 7 (3–13) 0.110 10 (6–11) 9 (7–11) 0.774
Median weight
(range) - kg
31.9 (4.1–60.0) 28.8 (17–38) 0.787 20.7 (3.0–42.3) 26.0 (3.9–44.4) 0.556 29 (20–40) 20 (12–32) 0.171
PCV 0.063 0.189 0.430
normal 46 89 20 24 5 18
decreased 1 12 4 1 1 1
Platelet count 0.127 0.138 0.999
normal 34 84 18 23 5 17
decreased 13 17 6 2 1 2
LDH 0.689 0.567 0.999
normal 23 53 15 13 4 11
increased 24 48 9 12 2 8
Stage 0.310 0.999 0.999
III-IV 15 41 4 4 2 8
V 32 60 20 21 4 11
Peripheral blood infiltration 0.129 0.496 0.160
no 17 50 6 4 5 8
yes 30 51 18 21 1 11
Bone marrow infiltration 0.647 0.791 0.999
no 20 47 5 6 3 9
yes 27 54 19 19 3 10
Extranodal involvement 0.004* 0.680 0.562
no 33 90 17 19 4 16
yes 14 11 7 6 2 3
Substage 0.198 0.484 0.999
a 27 69 14 17 5 14
b 20 32 10 8 1 5
Steroids before referral 0.284 0.038* 0.540
no 37 71 15 22 6 15
yes 10 30 9 3 0 4
Rescue protocols 0.275 0.696 0.400
untreated 1 8 1 1 1 1
one RP administered 10 21 3 8 1 5
more RP administered 5 23 4 5 0 2
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immunotherapy was particularly relevant in dogs with
high serum LDH levels, stage V disease, substage a,
and not previously treated with steroids.
The patients with all of the above characteristics
obtained the greatest survival advantage from the ad-
ministration of immunotherapy (median LSS, 480 vs
85 days; P < 0.001). Among dogs falling in two or
three of the above categories, those treated with
chemo-immunotherapy still had a significantly better
outcome, but the survival advantage was reduced
(median LSS, 435 vs 190 days; log-rank, P = 0.030). Fi-
nally, dogs falling in one or none of the above cat-
egories did not receive any significant benefit from
immunotherapy (median LSS, 374 vs 286 days, log-
rank, P = 0.573; Table 2; Fig. 1).
Dogs with nodal marginal zone lymphoma
Table 1 provides a summary of the characteristics of 49 dogs
with MZL using known or potential covariates for outcome.
Twelve (24.5%) dogs had been treated with steroids
before referral.
Twenty-four (48.9%) dogs received chemotherapy
alone and 25 (51.1%) chemo-immunotherapy. Dogs were
evenly balanced between groups according to possible
outcome variables, including the number of rescue pro-
tocols, with the exception of a lower percentage of dogs
receiving steroids before being treated with chemo-
immunotherapy (Table 1).
Median TTP was 147 days (95% CI, 47–247) for dogs
receiving chemotherapy and 227 days (95% CI, 165–289)
for those receiving chemo-immunotherapy (P = 0.082).
Table 1 Baseline characteristics of 222 dogs with B-cell lymphoma treated with chemotherapy alone or with chemo-
immunotherapy and stratified according to histotype (Continued)
Variable DLBCL (n = 148) MZL (n = 49) Follicular lymphoma (n = 25)
CH
(n = 47)
CH-IT
(n = 101)
P CH
(n = 24)
CH-IT
(n = 25)
P CH
(n = 6)
CH-IT
(n = 19)
P
Toxicity 0.167 0.667 0.211
none/grades 1–2 39 85 21 23 3 15
grades 3–4 5 15 3 2 2 3
grade 5 3 1 0 0 1 1
Abbreviations: DLBCL Diffuse large B-cell lymphoma, MZL marginal zone lymphoma, PCV Packed cell volume, LDH Lactate dehydrogenase, CH Chemotherapy, CH-
IT Chemo-immunotherapy, RP Rescue protocol
*Significant
Table 2 Score to evaluate the benefits of the treatment with chemo-immunotherapy in dogs with DLBCL and MZL
Serum LDH levels Normal (0) Increased (+ 1)
Stage III/IV (0) V (+ 1)
Substage b (0) a (+ 1)
Steroids before referral Yes (0) No (+ 1)
Dogs with diffuse large B-cell lymphoma
Score Median LSS 1-year SR 2-year SR 3-year SR
CH CH-IM P CH CH-IM CH CH-IM CH CH-IM
4 (n = 27) 85 480 < 0.001* 0% 57% 0% 15% 0% 0%
2–3 (n = 99) 190 435 0.030* 23% 50% 12% 18% 8% 11%
0–1 (n = 22) 286 374 0.573 40% 45% 40% 27% 25% 11%
All cases (n = 148) 165 413 0.001* 20% 51% 13% 19% 8% 10%
Dogs with marginal zone lymphoma
Score Median LSS 1-year SR 2-year SR 3-year SR
CH CH-IM P CH CH-IM CH CH-IM CH CH-IM
3–4 (n = 29) 160 680 < 0.001* 9% 77% 0% 36% 0% 12%
0–2 (n = 20) 560 172 0.165 56% 14% 38% 14% 25% 0%
All cases (n = 49) 254 399 0.245 30% 55% 16% 28% 10% 10%
Abbreviations: LDH, lactate dehydrogenase; LSS, lymphoma specific survival; SR, survival rate; CH, chemotherapy; CH-IM, chemo-immunotherapy
* Significant
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Median LSS was 254 days (95% CI, 69–442) for dogs re-
ceiving chemotherapy and 399 days (95% CI, 133–665)
for those receiving chemo-immunotherapy (P = 0.245).
There was no significant difference in TTP and LSS
between dogs with positive and negative DTH test.
The 1-year, 2-year and 3-year survival rates were, re-
spectively, 30, 16 and 10% for the chemotherapy group
and 55, 28 and 10% for the chemo-immunotherapy group.
When including in the survival analysis only the dogs fall-
ing in at least three of the 4 categories identified for
DLBCL, the survival advantage of chemo-immunotherapy
was statistically significant (median LSS, 680 vs 160 days,
log-rank, P < 0.001; Table 2; Fig. 1).
Dogs with follicular lymphoma
Among the 25 dogs with FL, 4 (16%) had been treated
with steroids before being referred.
Six (24%) dogs were treated with chemotherapy and
19 (76%) received chemo-immunotherapy. There was
a good balance between treatment arms regarding
demographic information and possible outcome vari-
ables, including the number of rescue protocols
(Table 1).
Median TTP was 168 days (95% CI, 1–386) for dogs
receiving chemotherapy and 273 days for those receiv-
ing chemo-immunotherapy (P = 0.076). Median LSS
was 200 days (95% CI, 1–462) for dogs receiving
Fig. 1 Survival curves of dogs with DLBCL and MZL grouped according to the proposed score
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chemotherapy and 436 days (95% CI, 201–671) for
those receiving chemo-immunotherapy (P = 0.011).
The 1-year, 2-year and 3-year survival rates were 0% for the
chemotherapy group, and 36, 27 and 18% for the chemo-
immunotherapy group.
On multivariable survival analysis, lack of immuno-
therapy was the only variable significantly associated
with increased risk of tumor-related death (HR = 5.2;
95% CI = 1.1–25.2; P = 0.039).
Toxicity
All dogs included in the study were evaluable for
toxicity.
Immunotherapy was well tolerated, with no reported
local or systemic AEs.
Chemotherapy was similarly well tolerated. There was
no significant difference among groups regarding grade
and frequency of AEs (Table 1).
Discussion
Immunotherapy is increasingly acknowledged as an ef-
fective treatment for several canine cancers including,
malignant melanoma, B-cell lymphoma, osteosarcoma,
and brain tumors [7, 8, 14–22]. Studies in the field have
unfortunately shown that not all dogs will have a sub-
stantial benefit, and it is incumbent upon clinicians to
decide whether a dog is or is not a candidate for
immunotherapy.
Herein, we present the results of a study aimed at
comparing the outcomes of dogs with B-cell lymphoma
receiving chemotherapy or chemo-immunotherapy. The
primary goal of this study was to identify the candidate
dogs that would benefit the most from chemo-
immunotherapy in the standard daily clinical practice
outside a trial setting. So far only two small clinical trials
on chemo-immunotherapy have been reported [7, 8].
The current study ranks among the largest per number
of dogs treated with the same product for a specific dis-
ease and confirms the efficacy and the good safety pro-
file of this treatment.
It was herein confirmed that DLBCL is the most com-
mon histotype in dogs, followed by MZL and FL. By
analyzing the whole population it was also confirmed
that stage III disease is quite infrequent, whereas stage V
was most commonly diagnosed (70.7%). It is likely that
an accurate staging leads to stage migration, having
prognostic and therapeutic implications, as documented
by the current data.
Overall, the present study demonstrates a significant
clinical benefit of immunotherapy. In particular, sub-
group analysis of LSS, comparing treatment arms using
a multivariable method, indicated the following.
It was found that immunotherapy conferred a survival
benefit in the majority of DLBCL cases. However, dogs
that benefited the most were those with stage V disease,
no systemic symptoms, a high serum LDH, and not pre-
viously treated with steroids. Interestingly, if these char-
acteristics were concurrent, vaccinated dogs had the
highest survival advantage (480 vs 85 days, respectively).
If two or three of the abovementioned characteristics
were present, the survival benefit for vaccinated dogs
was still significant, although to a lesser extent (435 vs
190 days, respectively). If only one or none of the above-
mentioned characteristics were present, there was no
demonstrable benefit of chemo-immunotherapy over
chemotherapy, although these cases represented a mi-
nority (n = 22).
It could be hypothesized that the stimulation of the
immune system may contribute to counteract the nega-
tive impact of well-known prognostic factors that com-
monly lead to a poor outcome if chemotherapy only is
administered. While chemotherapy effects only last as
long as the drugs remain in the body, immunotherapy
can provide long-term protection against cancer due to
the immune memory, overcoming the “honeymoon ef-
fect” provided in the short term by cytotoxic drugs,
more over if negative prognostic factors are present.
Chemotherapy fails when drug-resistant clones emerge,
preventing tumor cell eradication [23]. It may be pos-
sible that dogs with negative prognostic factors, such as
advanced disease stage and high LDH levels, are more
susceptible of developing chemo-resistance [2, 24, 25].
In these dogs, chemo-resistant clones may be eliminated
by cell-mediated immunotherapy because they can evade
neither immune surveillance nor immune response,
thereby providing a survival benefit.
Finally, the lower immunity in symptomatic dogs is a
plausible explanation to the suboptimal response to im-
munotherapy, and specific immune responses may be
abrogated by pre-treatment steroids.
These findings were also confirmed for the MZL cases:
vaccinated dogs survived significantly longer than unvac-
cinated dogs (680 vs 160 days, respectively; P < 0.001) if
three or four of the previously identified characteristics
were present. If 2 to none of those were present, there
was no significant benefit in administering chemo-
immunotherapy over chemotherapy.
In dogs with FL, a survival benefit of vaccine-
administration was demonstrated as well, however the
population was too small to evaluate the potential infer-
ence of other prognostic factors.
Finally, it must be reminded that, although chemo-
immunotherapy seems to provide better results than
chemotherapy for the majority canine B-cell lymphomas,
the 3-year survival rate remains largely unsatisfactory,
ranging from 0 to 12%; whereas the largest survival
benefit can be experienced in the short/medium-term
period. It is currently unknown whether re-vaccination
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or preparation of a new vaccine starting from nodal re-
lapses would improve long-term survival.
Our study has a number of limitations, such as the
small number of dogs included in some of the categories
and its retrospective nature. However, we have included
consecutive dogs diagnosed following a uniform ap-
proach and treated with standardized protocols.
Third, the evaluation of the immune response by the
DTH skin test, albeit clinically relevant, is operator-
dependent. Standardized and quantitative analyses are
warranted to reduce this constraint.
Last, LSS may have been influenced by tumor’s unre-
lated factors, including owners’ motivation and financial
concern. However, almost all dogs in both treatment
arms received at least one rescue protocol, thereby redu-
cing the risk of bias.
Conclusions
Our study shows a response and survival benefit of the
addition of active immunotherapy to chemotherapy in
dogs with B-cell lymphoma, possibly due to a different
and perhaps synergistic mechanism of action. In the fu-
ture, the development of new effective immunotherapeu-
tic strategies should take into account differences in
immune microenvironment between different lymphoma
molecular subtypes to find the best treatment for each
patient. A large-scale, double-blinded, randomized,
multi-institutional trial is essential for ascertaining the
efficacy of the presently described active immunotherapy
procedure and its clinical application.
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